Keliximab is a monoclonal antibody that targets CD4, leading to a transient reduction in the number of CD4+ T cells. Keliximab has been investigated in the research of severe asthmatics.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.